We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
Read MoreHide Full Article
Key Takeaways
TransMedics posted 20.7% Q2 revenue growth and raised the low end of its 2026 revenue outlook.
TMDX's adjusted operating margin fell 960 basis points as R&D spending nearly doubled year over year.
TransMedics' lower valuation offers support, but clinical timelines and higher spending add execution risk.
TransMedics Group, Inc. (TMDX - Free Report) is still expanding at a rapid pace, with Organ Care System adoption and transplant logistics supporting higher revenues. Management also raised the low end of its 2026 revenue outlook.
The trade-off is profitability. Spending on OCS Kidney, next-generation systems, clinical programs and international expansion is pressuring operating leverage, making the investment case more dependent on execution.
TMDX Revenue Growth Still Runs Strong
Second-quarter 2026 revenues rose 20.7% year over year to $189.9 million. Product revenues increased 15.7% to $111.2 million, while service revenues advanced 28.6% to $78.8 million.
Liver revenues climbed 27.7% to $148.2 million, and Transplant Logistics revenues increased 39% to about $41 million. TransMedics also raised the lower end of its 2026 revenue guidance to $737 million-$757 million, representing 22%-25% growth over 2025.
Image Source: Zacks Investment Research
TransMedics Margin Pressure Is Building
Growth is coming with heavier spending. Adjusted research and development expenses nearly doubled year over year to $31.6 million, driven by OCS Kidney, next-generation OCS and the ENHANCE and DENOVO programs.
Adjusted operating margin contracted 960 basis points to 13.6%. Management reduced its 2026 adjusted operating-margin outlook, excluding PAD Aviation, to 12.5%-14% from about 16%, mainly because of accelerated OCS Kidney investment.
TMDX Valuation Looks Less Demanding
TMDX trades at a forward 12-month price-to-sales ratio of 3.44, below 4.07 for its Zacks sub-industry and well below its five-year median of 7.86. The discount offers some valuation support after the stock’s weaker longer-term performance.
The broader medtech backdrop still matters. Boston Scientific Corporation (BSX - Free Report) reported 7.5% second-quarter 2026 net sales growth and a 28.4% adjusted operating margin, while Intuitive Surgical, Inc. (ISRG - Free Report) posted 19% revenue growth. Those results show why TMDX’s faster revenue growth must be weighed against its lower near-term operating leverage.
TransMedics Pipeline Adds Execution Risk
ENHANCE Part B and DENOVO could expand TransMedics’ addressable U.S. heart and lung market by roughly 2,000-5,000 cases annually. The opportunity remains dependent on regulatory approvals, enrollment and clinical execution.
OCS Kidney targets a larger market, but first clinical experience is not expected until later in 2027. International expansion and PAD Aviation add further opportunity, yet they also increase spending and integration demands before benefits are fully established.
Image Source: Zacks Investment Research
TMDX Signals Still Favor Caution
The bottom line is that TransMedics continues to deliver strong revenue growth, but its investment cycle is weighing on margins and increasing execution risk. A lower valuation helps, though the spending burden and clinical timelines argue for a measured stance.
TMDX currently carries a Zacks Rank #5 (Strong Sell), along with a Value Score of D, a Growth Score of F, a Momentum Score of D and a VGM Score of F. The weak Rank and Style Scores indicate an unfavorable near-term setup, and the Style Score framework suggests that cheaper valuation alone does not offset weaker growth and momentum characteristics.
View the Zacks #1 Rank List
Image: Bigstock
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
Key Takeaways
TransMedics Group, Inc. (TMDX - Free Report) is still expanding at a rapid pace, with Organ Care System adoption and transplant logistics supporting higher revenues. Management also raised the low end of its 2026 revenue outlook.
The trade-off is profitability. Spending on OCS Kidney, next-generation systems, clinical programs and international expansion is pressuring operating leverage, making the investment case more dependent on execution.
TMDX Revenue Growth Still Runs Strong
Second-quarter 2026 revenues rose 20.7% year over year to $189.9 million. Product revenues increased 15.7% to $111.2 million, while service revenues advanced 28.6% to $78.8 million.
Liver revenues climbed 27.7% to $148.2 million, and Transplant Logistics revenues increased 39% to about $41 million. TransMedics also raised the lower end of its 2026 revenue guidance to $737 million-$757 million, representing 22%-25% growth over 2025.
Image Source: Zacks Investment Research
TransMedics Margin Pressure Is Building
Growth is coming with heavier spending. Adjusted research and development expenses nearly doubled year over year to $31.6 million, driven by OCS Kidney, next-generation OCS and the ENHANCE and DENOVO programs.
Adjusted operating margin contracted 960 basis points to 13.6%. Management reduced its 2026 adjusted operating-margin outlook, excluding PAD Aviation, to 12.5%-14% from about 16%, mainly because of accelerated OCS Kidney investment.
TMDX Valuation Looks Less Demanding
TMDX trades at a forward 12-month price-to-sales ratio of 3.44, below 4.07 for its Zacks sub-industry and well below its five-year median of 7.86. The discount offers some valuation support after the stock’s weaker longer-term performance.
The broader medtech backdrop still matters. Boston Scientific Corporation (BSX - Free Report) reported 7.5% second-quarter 2026 net sales growth and a 28.4% adjusted operating margin, while Intuitive Surgical, Inc. (ISRG - Free Report) posted 19% revenue growth. Those results show why TMDX’s faster revenue growth must be weighed against its lower near-term operating leverage.
TransMedics Pipeline Adds Execution Risk
ENHANCE Part B and DENOVO could expand TransMedics’ addressable U.S. heart and lung market by roughly 2,000-5,000 cases annually. The opportunity remains dependent on regulatory approvals, enrollment and clinical execution.
OCS Kidney targets a larger market, but first clinical experience is not expected until later in 2027. International expansion and PAD Aviation add further opportunity, yet they also increase spending and integration demands before benefits are fully established.
Image Source: Zacks Investment Research
TMDX Signals Still Favor Caution
The bottom line is that TransMedics continues to deliver strong revenue growth, but its investment cycle is weighing on margins and increasing execution risk. A lower valuation helps, though the spending burden and clinical timelines argue for a measured stance.
TMDX currently carries a Zacks Rank #5 (Strong Sell), along with a Value Score of D, a Growth Score of F, a Momentum Score of D and a VGM Score of F. The weak Rank and Style Scores indicate an unfavorable near-term setup, and the Style Score framework suggests that cheaper valuation alone does not offset weaker growth and momentum characteristics.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.